Current view: Indications for extracorporeal lipid apheresis treatment

Clinical Research in Cardiology Supplements

Volumn 7, Issue SUPPL.1, 2012, Pages 15-19

  Schettler, Volker ^a   Neumann, C L ^a   Hulpke Wette, M ^b   Hagenah, G C ^a   Schulz, E G ^a   Wieland, E ^c  

^a Center of Nephrology Göttingen   (Germany)

^b Pediatrician and pediatric cardiology practice   (Germany)

^c KLINIKUM STUTTGART   (Germany)

Author keywords

Atherosclerosis; Indication; LDL; Lipid apheresis; Lp(a)

Indexed keywords

ANTILIPEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A;

APHERESIS; ARTICLE; ATHEROGENESIS; DIET THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; THROMBOSIS; BLOOD; CONSENSUS; DISEASE COURSE; ECONOMICS; EXTRACORPOREAL CIRCULATION; GERMANY; HYPERCHOLESTEROLEMIA; METHODOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REGISTER; REIMBURSEMENT;

BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CONSENSUS; DISEASE PROGRESSION; EXTRACORPOREAL CIRCULATION; GERMANY; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); PRACTICE GUIDELINES AS TOPIC; REGISTRIES; REIMBURSEMENT MECHANISMS;

EID: 84872193917     PISSN: 18610706     EISSN: 18610714     Source Type: Journal    
DOI: 10.1007/s11789-012-0046-6     Document Type: Article

References (37)

1. de Gennes JL, Touraine R, Maunand B et al (1967) Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis as heroic treatment. Bull Mem Soc Med Hop Paris 118: 1377-1402.
2. Richter WO, Jacob BG, Ritter MM et al (1993) Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42: 888-894.
3. Gordon BR, Kelsey SF, Dau PC et al (1998) Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol 81: 407-411.
4. Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolemia. Lancet 2: 1005-1007.
5. Yokoyama S, Hayashi R, Satani M et al (1985) Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 5: 613-622.
6. Mabuchi H, Michishita I, Takeda M et al (1987) A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 68: 19-25.
7. Eisenhauer T, Armstrong VW, Wieland H et al (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65: 161-168.
8. Klingel R, Mausfeld P, Fassbender C et al (2004) Lipidfiltration-safe and effective methodology to perform lipid apheresis. Transfus Apher Sci 30: 245-254.
9. Bosch T, Schmidt B, Kleophas W et al (1997) LDL hemoperfusion-a new procedure for LDL apheresis: first clinical application of an LDL adsorber compatible with human whole blood. Int J Artif Organs 21: 977-982.
10. Kobayashi A, Nakatani M, Furuyoshi S et al (2002) In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein hemoperfusion. Ther Apher 6: 365-371.
11. Krebs A, Krebs K, Keller F (2004) Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int J Artif Organs 27: 137-148.
12. Julius U, Metzler W, Pietzsch J et al (2002) Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 25: 1180-1188.
13. Thompson GR (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198: 247-255.
14. Steinberg D (2006) Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 47: 1339-1351.
15. Erqou S, Kaptoge S, Perry PL et al (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423.
16. Robinson JG, Wang S, Smith BJ et al (2009) Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol 53: 316-322.
17. Pasternak R (2002) Adult treatment panel II versus adult treatment panel III: what has changed and why? Am J Cardiol 89: 3C-7C.
18. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110: 227-239.
19. Thompson GR, Catapano A, Saheb S et al (2010) Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 21: 492-498.
20. Thompson GR (2010) Lipoprotein apheresis. Curr Opin Lipidol 21: 487-491.
21. Schettler V, Jaeger BR, Klingel R (2009) The German lipid apheresis registry-remaining to be established. Atheroscler Suppl 10: 59-61.
22. Schettler V, Wieland E, Armstrong VW et al (2002) First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 6: 381-383.
23. Gemeinsamer-Bundesausschuss (2003) Bekanntmachung des Bundesausschusses der Ärzte und Krankenkassen über eine Änderung der Richtlinien über die Bewertung ärztlicher Untersuchungs- und Behandlungsmethoden gemäß § 135 Abs. 1 des Fünften Buches Sozialgesetzbuch (SGB V; BUB-Richtlinien). BAnz: 14486.
24. Gemeinsamer-Bundesausschuss (2009) Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Richtlinie Methoden vertragsärztliche Versorgung: Apherese bei isolierter Lp(a)-Erhöhung für Studienteilnehmer. BAnz 128: 3005.
25. Schettler V, Wieland E (2003) LDL-Aphereseverfahren. In: Hörl WH, Wanner C (eds) Dialyseverfahren in Klinik und Praxis, 6 edn. Thieme, Stuttgart, pp 116-133.
26. Ito MK, McGowan MP, Moriarty PM (2011) Management of familial hypercholesterolemias in adult patients: recommendations from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 5: S38-45.
27. Goldberg AC, Hopkins PN, Toth PP et al (2011) Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the national lipid association expert panel on familial hypercholesterolemia. J Clin Lipidol 5: S1-8.
28. Moriarty PM, Gibson CA (2001) Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses. Curr Atheroscler Rep 3: 156-162.
29. Bosch T, Wendler T (2004) State of the art of low-density lipoprotein apheresis in the year 2003. Ther Apher Dial 8: 76-79.
30. Thompsen J, Thompson PD (2006) A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189: 31-38.
31. Mabuchi H, Higashikata T, Kawashiri MA (2004) Clinical applications of long-term LDL apheresis on and beyond refractory hypercholesterolemia. Transfus Apher Sci 30: 233-243.
32. Vella A, Pineda AA, O'Brien T (2001) Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc 76: 1039-1046.
33. Clarke R, Peden JF, Hopewell JC et al (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528.
34. Akdim F, Visser ME, Tribble DL et al (2010) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105: 1413-1419.
35. Stegmayr B, Ptak J, Wikstrom B et al (2008) World apheresis registry 2003-2007 data. Transfus Apher Sci 39: 247-254.
36. Rock G, Clark B, Sutton D (2003) The Canadian apheresis registry. Transfus Apher Sci 29: 167-177.
37. Korach JM, Guillevin L, Petitpas D et al (2000) Apheresis registry in France: indications, techniques, and complications. French registry study group. Ther Apher 4: 207-210.